TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean change in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT image sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain intensity at 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the digital communication app
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the digital communication app
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CAARS: Inv Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inappropriate drug prescription and use indicators
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with corrected PTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SF36 physical component summary (PCS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: salicylic acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum thromboxane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PFA-100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abdominal working space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resting Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success Rate of ACTIVA BIOACTIVE and Fuji IX Extra GIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Cholesterol : HDL-C Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child standardized body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Survival
Endpoint domain: Mortality/survival
Primary endpoint: Numbers of participants with polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: composite outcomes (death, re-infarction, recurrent ischemia)
Endpoint domain: Mortality/survival
Primary endpoint: re-hospitalization with ACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of women diagnosed with pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Degree of patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours of Metformin After Single Dose Administration (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity of Metformin After Single Dose Administration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of AdalatCR treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD34+ Endothelial Progenitor Cells Number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD 34+ Cell Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of cancer initiating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to LiFE activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Staphylococcus aureus infection
Endpoint domain: Adverse events/effects
Primary endpoint: Serum 25 (OH) D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healing of surgical sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infection of surgical sites
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of Pain Neuroscience
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cardiac transplantation
Endpoint domain: Mortality/survival
Primary endpoint: change in accuracy (%) during a cognitive task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in reaction time (milliseconds) during a cognitive task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency and severity of treatment-emergent adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Perfusion Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Incidence of Cervical Intraepithelial Neoplasia (CIN) 2/3 or Worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in nasal responses to live attenuated influenza virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the Aptima HSV 1 & 2 Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and grade of contractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in the Percentage of Wound Bed Surface Area (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Surgical Site Complications (SSCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of GBM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin assessment of positive tumors in NIRF fluorescent-guided surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose (MTD) of AZD8055
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interdental papilla height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection rate of mosquitoes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyst counts in infected mosquitoes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period prevalence and density of gametocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of M1 (Metastatic Disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change of Resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concordance in detection of molecular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis results negative for methamphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Treponema pallidum infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with acute radiation toxicity of Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with late radiation toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Local Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: exercise-induced systolic pulmonary arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients completing PET/MR scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of CIPNM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar Cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence/absence of S. aureus strains in the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Period duration to clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum isometric strength differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Range differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Irritation (Erythema and Edema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in parent reported social responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in parent reported socialization subscale scores of the VABS-II
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Complications related to peripheral vascular catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in white blood cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-drug antibody development
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Participants That Successfully Completed Remote Follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Number of Participants Who Ever Completed Remote Follow-up Requests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Overall Diurnal Intraocular Pressure (IOP) at Week 4 (Worse Eye)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: improvement in perfused vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bronchial exhale nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peripheral exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of treatment on the entire colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity according to NCI CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of successful implantations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Insulin-like Growth Factor-1 (IGF-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute Change in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change in Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Success According to the Dichotomized Investigator Global Assessment [IGA] at End of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Platelet reaction units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recall of designated facts during informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: whole body peripheral glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fuel oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Schiff Sensitivity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Total Dumping score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular AT2R expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: endothelial dysfunction reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Yale Global Tic Severity Scale Total Tic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary non-function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic Cholangiopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hard exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Posaconazole Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Posaconazole Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pink esthetic score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute Change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in QT Interval Corrected for Heart Rate (QTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants with Change from Baseline in T-wave Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants with Occurrence of Abnormal U-wave Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with guideline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in Visual Analog Scale (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perspective of rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of time to reach criteria for discharge from hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Radiotracer Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of patients prescribed anticoagulant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: local treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Gastro-Intestinal Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success of colonoscopy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in knowledge regarding physical activity during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety of S-Caine Peel
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of Preview Strep A Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Attention to Response Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean deviation of automated visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intracellular HO-1 expression in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HO-1 level in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokines levels measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in regional liver perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in perfusion defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patency of the grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding tolerance - Gastric residuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume of formula consumed in a day vs. goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tube feeding interruptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of triggering (ten active fist test / 30 second active fist test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength (hand dynamometer and pinchmeter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Arterial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-preparation skin swab
Endpoint domain: Adverse events/effects
Primary endpoint: Markers of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FBF Ratio in Response to Acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Score of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily Delta Sequential Organ Failure Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Health Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in children's physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FOG-Q subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of falling
Endpoint domain: Adverse events/effects
Primary endpoint: Global relief of GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Growth at 4 months corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfed, full or partly, and solid food at 4 months PMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of completed DOT interactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants completing recommended duration of DOT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall response rate (ORR)
Endpoint domain: Physiological/clinical
Primary endpoint: Lipid peroxidation in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypercapnic hypoxic ventilatory sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline to Week 8 in Mean 24-hour SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Reporting Solicited Adverse Events Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects Achieving HI Titers ≥1:40 Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Fear of Anxiety-Related Body Sensations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subject incidence of adverse events
Endpoint domain: Adverse events/effects